PIQHASSO

PQR309 AND ERIBULIN FOR LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE AND TRIPLE NEGATIVE BREAST CANCER

THIS STUDY IS AN OPEN-LABEL, NON RANDOMIZED, MULTI-CENTER, PHASE 1/2B (DOSE ESCALATION FOLLOWED BY EXPANSION PART) STUDY EVALUATING CLINICAL SAFETY, EFFICACY AND PHARMACOKINETICS OF PQR309 IN COMBINATION WITH STANDARD DOSE OF ERIBULIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE (ESCALATION PART) AND TRIPLE NEGATIVE BREAST CANCER (EXPANSION PART). LEGAL STUDY SPONSOR IS PIQUR THERAPEUTICS AG.

https://clinicaltrials.gov/study/NCT02723877

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

BREAST

I/IIb

Spain, UK

Recruitment closed

CLINICAL TRIAL DETAILS

PRESS RELEASE

SCIENTIFIC IMPACT

SABCS 2016 poster: https://39f1664e-7766-40bf-9b5a-e3575d54bba6.usrfiles.com/ugd/39f166_785da2225e9d4ca48c6211491f8754d0.pdf

BLOG ARTICLES RELATED

TRIAL SITES

Hospital Universitario Ramón y Cajal (Spain) | Instituto Valenciano de Oncología (IVO) (Spain) | Hospital Universitari Vall D'Hebron (Spain) | Institut Català d'Oncologia L'Hospitalet (ICO) (Spain) | Churchill Hospital, Oxford (UK) | Barts Cancer Institute (UK)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley